BIBW 2992 is one orally administered.

BIBW 2992 is one orally administered, irreversible dual inhibitor of epidermal growth factor receptor and human epithelial receptor 2 tyrosine kinases. It is the first irreversible EGFR TKI for the phase III third / fourth – line NSCLC is achieved .

References1 Li D et al. ‘BIBW2992 irreversible inhibitor EGFR/HER2 highlyeffective in preclinical lung cancer models. ‘Oncogene 2008; 27:4702-47112 Shih JY et al. ‘A phase II study of BIBW 2992, a novel irreversible two EGFR and HER2 tyrosine kinase inhibitor , poster session in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of 1 line of chemotherapy ‘Poster Discussion 2009, 2009, Session Time:. 08.00 clock to 12# 8013.On that Public Library of ScienceThe Public Library of Science (PLoS non profit non-profit organization of scientists and doctors is required to the world of scientific and medical literature a freely accessible public resource.

Other entries from category "trichology":

Random entries